Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L. · 2020

Read Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. by Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7091888.txt.

Introduction

Tai and co-authors characterised the receptor-binding domain of the new coronavirus spike protein, in Cellular and Molecular Immunology. The spike grips the ACE2 receptor to enter human cells, making its binding region a prime target for drugs and vaccines. The team made the binding-domain protein and tested how it behaves.

The SARS-CoV-2 binding domain attached to human and bat ACE2 more strongly than the older SARS virus version did. Added as a free protein, it blocked both viruses from latching onto cells. Antibodies raised against the SARS binding domain also reacted with the new one and could neutralise the new virus. The results support vaccines built on this protein piece.

Catalog record

CREATORTai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7091888

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine By Wanbo Tai, Lei He, Xiujuan Zhang, Jing Pu, Denis Voronin, Shibo Jiang, Yusen Zhou, Lanying Du Published in: Cellular and Molecular Immunology DOI: 10.1038/s41423-020-0400-4 ABSTRACT Abstract The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV). The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Here, we identified the receptor-binding domain (RBD) in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection. Keywords: 2019 novel coronavirus, SARS-CoV-2, spike protein, receptor-binding domain, viral inhibitor, cross-neutralization Subject terms: Viral infection, Immunotherapy INTRODUCTION Three highly pathogenic human coronaviruses (CoVs) have been identified so far, including Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and a 2019 novel coronavirus (2019-nCoV), as previously termed by the World Health Organization (WHO).1–3 Among them, SARS-CoV was first reported in Guangdong, China in 2002.4 SARS-CoV caused human-to-human transmission and resulted in the 2003 outbreak with about 10% case fatality rate (CFR),1 while MERS-CoV was reported in Saudi Arabia in June 2012.5 Even though with its limited human-to-human transmission, MERS-CoV showed a CFR of about 34.4%.2 The 2019-nCoV was first reported in Wuhan, China in December 2019 from patients with pneumonia,6 and it has exceeded both SARS-CoV and MERS-CoV in its rate of transmission among humans.7 2019-nCoV was renamed SARS-CoV-2 by Coronaviridae Study Group (CSG) of the International Committee on Taxonomy of Viruses (ICTV),8 while it was renamed HCoV-19, as a common virus name, by a group of virologists in China.9 The disease and the virus causing it were named Coronavirus Disease 2019 (COVID-19) and the virus responsible for COVID-19 or the COVID-19 virus, respectively, by WHO.3 As of March 5, 2020, a total of 95,333 confirmed cases of COVID-19 were reported, including 3,282 deaths, in China and at least 85 other countries and/or territories.7 Currently, the intermediate host of SARS-CoV-2 is still unknown, and no effective prophylactics or therapeutics are available. This calls for the immediate development of vaccines and antiviral drugs for prevention and treatment of COVID-19. A coronavirus contains four structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins.2,10,11 Among them, S protein plays the most important roles in viral attachment, fusion and entry, and it serves as a target for development of antibodies, entry inhibitors and vaccines.1,12–17 The S protein mediates viral entry into host cells by first binding to a host receptor through the receptor-binding domain (RBD) in the S1 subunit and then fusing the viral and host membranes through the S2 subunit.16,18,19 SARS-CoV and MERS-CoV RBDs recognize different receptors. SARS-CoV recognizes angiotensin-converting enzyme 2 (ACE2) as its receptor, whereas MERS-CoV recognizes dipeptidyl peptidase 4 (DPP4) as its receptor.20,21 Similar to SARS-CoV, SARS-CoV-2 also recognizes ACE2 as its host receptor binding to viral S protein.22 Therefore, it is critical to define the RBD in SARS-CoV-2 S protein as the most likely target for the development of virus attachment inhibitors, neutralizing antibodies, and vaccines. In this study, we identified the RBD fragment in SARS-CoV-2 S protein and found that the recombinant RBD protein bound strongly to human ACE2 (hACE2) and bat ACE2 (bACE2) receptors. In addition, it blocked the entry of SARS-CoV-2 and SARS-CoV into their respective hACE2-expressing cells, suggesting that it may serve as a viral attachment inhibitor against SARS-CoV-2 and SARS-CoV infection. Moreover, we demonstrated that SARS-CoV RBD-specific polyclonal antibodies cross-reacted with SARS-CoV-2 RBD protein and inhibited SARS-CoV-2 entry into hACE2-expressing cells. We have also shown that SARS-CoV RBD-specific polyclonal antibodies could cross-neutralize SARS-CoV-2 pseudovirus infection, suggesting the potential to develop SARS-CoV RBD-based vaccine for prevention of infection by SARS-CoV-2 and SARS-CoV. RESULTS AND DISCUSSION By alignment of the RBD sequences of SARS-CoV and SARS-CoV-2, we identified the region of SARS-CoV-2 RBD at residues 331 to 524 of S protein (Fig. 1a). We then constructed a recombinant RBD protein containing codon-optimized RBD sequences with a C-terminal Fc of human IgG1 (hFc) using pFUSE-hIgG1-Fc2 expression vector, expressed the protein in mammalian cell 293T, and purified it from cell culture supernatant using protein A affinity chromatography. Similar to SARS-CoV and MERS-CoV RBD protein controls, SARS-CoV-2 RBD protein had high expression with strong purity (Fig. 1b). Notably, only SARS-CoV-2 and SARS-CoV RBDs were recognized by SARS-CoV RBD-specific, but not MERS-CoV RBD-specific, polyclonal antibodies (Fig. 1c), whereas only MERS-CoV RBD was recognized by MERS-CoV RBD-immunized polyclonal antibodies (Fig. 1d), suggesting the cross-reactivity of SARS-CoV RBD-specific antibodies with SARS-CoV-2 RBD protein. [Figure: Characterization of SARS-CoV-2 RBD. a Multiple sequence alignment of RBDs of SARS-CoV-2, SARS-CoV, and MERS-CoV spike (S) proteins. GenBank accession numbers are QHR63250.1 (SARS-CoV-2 S), AY278488.2 (SARS-CoV S), and AFS88936.1 (MERS-CoV S). Variable amino acid residues between SARS-CoV-2 and SARS-CoV are highlighted in cyan, and conserved residues among SARS-CoV-2, SARS-CoV, and MERS-CoV are highlighted in yellow. Asterisks represent fully conserved residues, colons represent highly conserved residues, and periods represent lowly conserved residues. The alignment was performed using Clustal Omega. SDS-PAGE (b) and Western blot (c, d) analysis of SARS-CoV-2 RBD. The protein molecular weight marker (kDa) is indicated on the left. SARS-CoV and MERS-CoV RBDs were included as controls. Antisera (1:3,000 dilution) from mice immunized with SARS-CoV RBD (c) and MERS-CoV RBD (d) were used for Western blot analysis] Four experiments were performed to detect the binding between SARS-CoV-2 RBD and hACE2 receptor. First, we tested if stably transfected hACE2/293T cells expressed hACE2 by flow cytometry analysis. Since 293T cells alone did not express either hACE2 or hDPP4, they could not be recognized by anti-hACE2 or anti-hDPP4 antibodies (Fig. 2a (left panel)). Only hACE2/293T cells, but not hDPP4/293T cells, expressed hACE2, which was recognized by an anti-hACE2 antibody (Fig. 2a (middle panel)), whereas only hDPP4/293T cells, but not hACE2/293T cells, expressed hDPP4 and was, correspondingly, recognized by an anti-hDPP4 antibody (Fig. 2a (right panel)). These data confirmed the expression of hACE2 in hACE2/293T cells and the expression of hDPP4 in hDPP4/293T cells. Second, we used these hACE2/293T cells to detect the binding of SARS-CoV-2 RBD protein to cell-associated hACE2 by flow cytometry analysis and immunofluorescence staining. Similar to SARS-CoV RBD, SARS-CoV-2 RBD bound to hACE2/293T cells expressing hACE2 (Fig. 2b (left and middle panels)), but not to hDPP4/293T cells expressing hDPP4 (Fig. 2c (left and middle panels)). Furthermore, the binding between SARS-CoV-2 RBD and hACE2-expressing 293T cells was much stronger than the binding between SARS-CoV RBD and

Read the complete text